Study finds, Oral erythromycin & Domperidone Effecient for t
Domperidone and erythromycin are often used in premature infants as prokinetic medications to feed intolerance. This study aimed at comparing the effectiveness of domperidone and eryThromycin taken orally for the treatment of preterm infant's feeding intolerance.

This retrospective cohort research included preterm neonates with a birthweight of less than 1800 grams and gestational age less than 37 weeks. The primary outcome was the time to establish full enteral feeding (150 ml/kg/day) after initiating oral domperidone or erythromycin for the treatment of feeding intolerance in preterm infants. The second result was unfavorable effects of domperidone with erythromycin.

--Among the 150 preterm neonates enrolled in this study, 66 received domperidone, and 84 received erythromycin.

--The baseline characteristics and comorbidities were not significantly different between the two groups; however, the gestational age at birth of neonates in the domperidone group was significantly lower than that of those in the erythromycin group.

--The time to establish full enteral feeding did not differ between the domperidone (11 days) and erythromycin (10 days).

--No major adverse effects were noted. There were only three preterm infants who had elevated liver enzymes in each group, but the difference between groups was not significant.

Finally, oral domperidone's effectiveness was promising equivalent to oral erythromycin and is seemingly a therapy choice for premature neonate intolerance feeding. Large, controlled, randomized trials are nonetheless necessary for confirmation of domperidone efficacy and safety in this population.